MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Does Macronutrient dietary Intake of patients with Parkinson disease correlates with the cognitive function (MoCA)?

    C. López Botello, S. Castillo Torres, I. Estrada Bellmann, B. Chávez Luevanos (Monterrey, Mexico)

    Objective: Analyze the correlation between macronutrient dietary intake and cognitive function of patients with Parkinson’s Disease Background: Several studies have shown that implementing a healthy…
  • MDS Virtual Congress 2021

    Movement disorders in demyelination: A case series of ten patients

    R. Singh, S. Pandey (New Delhi, India)

    Objective: To observe the association of various movement disorder with demyelinating disease. Background: Movement disorders in demyelinating diseases are not an unheard entity, but besides…
  • MDS Virtual Congress 2021

    Evaluating palliative care needs in patients with Parkinson’s disease and related disorders

    K. Kay, A. Killoran (Iowa City, USA)

    Objective: To assess the palliative care needs in patients with Parkinson’s disease and related disorders at an academic movement disorders clinic. Background: There is growing…
  • MDS Virtual Congress 2021

    The OASIS (OpicApone in Sleep dISorder) study in Parkinson’s disease: design and rationale of an open-label, single-arm, pilot trial

    R. Costa, C. Trenkwalder, J. Ferreira, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the effects of opicapone (OPC) treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’. Background: OPC proved to be…
  • MDS Virtual Congress 2021

    Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II clinical trial

    J. Greenland, E. Cutting, S. Kadyan, S. Bond, A. Chhabra, C. Williams-Gray (Cambridge, United Kingdom)

    Objective: To design a clinical trial to test the concept that the immune system is integral in the progression of Parkinson’s disease (PD) and establish…
  • MDS Virtual Congress 2021

    Cinpanemab in Early Parkinson’s Disease: Phase 2 SPARK Study Results

    A. Lang, A. Siderowf, E. Macklin, W. Poewe, D. Brooks, H. Fernandez, O. Rascol, N. Giladi, F. Stocchi, C. Tanner, R. Postuma, D. Simon, E. Tolosa, B. Mollenhauer, M. Byrne, K. Fraser, J. Xiao, I. Sapir, J. Inra, R. Hutchison, M. Yang, T. Fox (Toronto, Canada)

    Objective: To evaluate cinpanemab (BIIB054) efficacy and safety. Background: Aggregated alpha-synuclein (α-syn), a major constituent of Lewy bodies, is thought to play a central role…
  • MDS Virtual Congress 2021

    Decreased expression of trace amines receptors on lymphocytes in Parkinson’s disease

    Z. Muruzheva, I. Ivleva, V. Maystrenko, O. Tumashova, M. Karpenko (Saint-Petersburg, Russian Federation)

    Objective: To determine the expression of TAAR1 and TAAR2 mRNA in leukocytes of patients with Parkinson's disease, depending on the stage of the disease and…
  • MDS Virtual Congress 2021

    RESPONDING TO COVID-19: THE “ALMEIDA-SANG EQUATION” TO PREDICT TOTAL DISEASE SEVERITY IN PARKINSON’S

    K. Sangarapillai, B. Norman, Q. Almeida (Waterloo, Canada)

    Objective: To predict total disease severity in Parkinson’s disease (PD) for online assessments. Background: Assessment (and hence management) of PD has largely been affected by…
  • MDS Virtual Congress 2021

    Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics

    S. Bakshi, PH. Vander Graaf (Breda, Netherlands)

    Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…
  • MDS Virtual Congress 2021

    Determination of the motor status after the implementation Levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease using a Machine learning Algorithm

    E. Efthymiopoulou, A. Antonoglou, B. Loupo, A. Bougea (Athens, Greece)

    Objective: Aim of this study was to develop a random forest (RF)-based PD model to determine the postoperative motor outcome at 2 years follow-up after…
  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley